openPR Logo
Press release

Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens

03-28-2022 10:22 AM CET | Health & Medicine

Press release from: Creative Diagnostics

As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens that are well validated in double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). The newly introduced antigens consist of five of the most common staphylococcus aureus enterotoxins and are ideal for in vitro detection and diagnostic studies.

Staphylococcus aureus is a Gram-positive spherical bacterium about 1 µm in diameter that forms clusters. Staphylococci are ubiquitous in the environment and can be found in air, dust, sewage, water, and environmental surfaces. It lives in humans and livestock and is commonly found in the upper respiratory tract and skin. Staphylococcus aureus is one of the leading causes of foodborne bacterial poisoning worldwide. The most prominent virulence factors associated with S. aureus are staphylococcal enterotoxins (SEs), which cause toxic shock-like syndrome and are associated with food poisoning.

SEs are potent parenteral toxins synthesized by Staphylococcus aureus throughout the logarithmic growth phase or during the transition from exponential to stationary phase. SEs and enterotoxin-like (SEls) are globular single-chain proteins with low molecular weight (19-29 kDa). These SEs have remarkable heat and acid resistance. Staphylococcal enterotoxins have been proposed to be named according to their emetic activity, and only superantigens that cause emesis after oral administration in primate models will be named SEs. The repertoire of S. aureus SEs/SEls includes 22 members, excluding molecular variants.

The most common staphylococcal enterotoxins are SEA and SEB. TSST-1, originally designated SEF, lacks emetic activity. SEs act not only as potent gastrointestinal toxins, but also as superantigens that bind to class II MHC molecules on antigen-presenting cells and stimulate T-cell proliferation. If this stimulation persists, a massive cytokine overload occurs, precluding the clinical features of toxic shock syndrome.

Creative Diagnostics offers five different enterotoxin types (SEA, SEB, SEC, SED and SEE). Products such as Native Staphylococcus aureus Enterotoxin A (SEA) (DAG-WT619), Recombinant Staphylococcus aureus Enterotoxin B (SEB) (DAG-WT627), Native Staphylococcus aureus Enterotoxin C2 (SEC2) (DAG-WT621), Recombinant Staphylococcus aureus Enterotoxin D (SED) (DAG-WT629), and Native Staphylococcus aureus Enterotoxin E (SEE) (DAG-WT624) are all available at Creative Diagnostics. They are highly purified staphylococcal enterotoxins (over 95% purity) and have less cross-reactivity with other enterotoxin types.

"Our entire product line is designed for research uses, and this new product is now offered to our global customers to improve the efficacy of in vitro detection and diagnostic studies. In combination with our other antigens products, these new staphylococcal enterotoxin antigens can help us to better serve our scientific customers," said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics. "We're glad to enable our customers to have reliable results, and we will continue to add new ones to our existing offering."

If you want to know more details about staphylococcal enterotoxin antigen products list or have any other questions about our research materials, please visit Creative Diagnostics at https://www.creative-diagnostics.com.

Creative Diagnostics
NY 11967, USA
Thomas Schmitt

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens here

News-ID: 2587053 • Views: 146

More Releases from Creative Diagnostics

Creative Diagnostics Launches Antibody-dependent Enhancement Assay Services
As a consulting and experimental service provider specializing in virology and microbiology, Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay. Flow cytometry, plaque assay or qPCR method are used to evaluate the ADE effect of test articles on virus infection in Fc receptor bearing cells. Antibody-dependent enhancement mainly refers to effects in the body caused by pathogen infection. In 1964, Hawkes and his team at the Australian National
Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. All of these new products are produced using standardized production processes to ensure the highest quality. Tests developed using these reagents can assist researchers in routine diagnostics and NiV vaccine development. Nipah virus (NiV) was initially isolated and identified in 1999 during an outbreak
Creative Diagnostics Broadens Its Portfolio with New Pseudotyped GFP HPV
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently introduces new Pseudotyped GFP HPV for immunogenicity assessment in vaccine trials. This new series of HPV reporter virus particles can be used for measuring neutralizing anti-HPV antibodies in pseudovirion-based neutralization assays. Human papillomaviruses (HPVs) are double-stranded non-enveloped DNA viruses that infect keratinocytes of stratified squamous epithelia. Immunogenicity assessments in vaccine trials have focused
Creative Diagnostics Launches Fluorescently Labeled Gold Nanoparticles for Cellu …
With years of experience in the pharmaceutical and life science sector, Creative Diagnostics introduces a series of fluorescently labeled gold nanoparticles for efficient cell uptake, such as DiagNano™ Fluorophore Labeled Gold Nanoparticles, 10 nm, Cellular Uptake(GFL-10-CU), and DiagNano™ Fluorophore Labeled Gold Nanoparticles, 50 nm, Cellular Uptake (GFL-50-CU). These new products can be potentially used for cancer diagnostics, studies, and immunoassays. Colloidal and intracellular gold nanoparticles can be validated by confocal microscopy.

All 5 Releases


More Releases for Staphylococcus

Staphylococcus Aureus Testing Market In-Depth Market Research Report 2027
A wide range of human clinical infection caused by Staphylococcus Aureus such as Skin, soft tissue, bacteremia, infective endocarditis and others are the major infection caused by Staphylococcus Aureus. The increased use of Staphylococcus Aureus testing in the diagnosis of staph infection grow rapidly, due to the availability of the various advanced test to screen the pathogen efficiently. There is a number of tests present in the market for Staphylococcus
Methicillin-resistant Staphylococcus Aureus Therapeutics Pipeline Analysis 2018
MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital
Vancomycin-Resistant Staphylococcus aureus Infections Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2017, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape. Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs) . This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant (not killed) to the antibiotic medicine vancomycin. Risk factors include taking strong antibiotics the wrong
Market Forecast Report on Staphylococcus Aureus Testing Market 2017 – 2027
A wide range of human clinical infection caused by Staphylococcus Aureus such as Skin, soft tissue, bacteremia, infective endocarditis and others are the major infection caused by Staphylococcus Aureus. The increased use of Staphylococcus Aureus testing in the diagnosis of staph infection grow rapidly, due to the availability of the various advanced test to screen the pathogen efficiently. There is a number of tests present in the market for Staphylococcus
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections-Pipelin …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections-Market Insights, Epidemiology and Market Forecast-2025”. This report provides an overview of the disease and in depth research related to Hospital Acquired Methicillin Resistant Staphylococcus Aureus Infections for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. Request For Sample Report: